Basic Information
| LncRNA/CircRNA Name | LINC01296 |
| Synonyms | DUXAP9, LINC01296, FLJ39632, lncRNA-CTD903 |
| Region | GRCh38_14:19062316-19131167 |
| Ensemble | ENSG00000225210 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot |
| Sample | prostate cancer tissues, cell lines (22Rv1 and LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | LINC01296-expression level was higher in prostate cancer tissues and prostate cancer cells than in adjacent nontumor tissues and immortalized normal prostate stromal WPMY1 cells. Multivariate analysis showed that LINC01296 expression was an independent predictor of biochemical recurrence-free survival in prostate cancer. |
| Pubmed ID | 28392705 |
| Year | 2017 |
| Title | Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis |
External Links
| Links for LINC01296 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |